Clinical Trials

Inclusion Criteria:

- Patient or patient's legally authorized representative (LAR) or proxy (e.g., spouse or
legal guardian) has the ability to understand the purpose and risks of ALZ-NET and
provide signed and dated informed consent and authorization to use protected health
information (PHI) in accordance with national and local patient privacy regulations.

- Patient is at least 18 years of age at the time of informed consent.

- Patient has a diagnosis of MCI or dementia with clinical suspicion of AD as
contributing pathology and (1) is being evaluated for treatment or, (2) will be
initiating treatment, or (3) has already initiated treatment with novel FDA-approved
AD therapies in real-world clinical practice.

- If treatment is initiated at the time of consent, patient meets appropriate label
requirements and treatment follows appropriate use recommendations for novel
FDA-approved AD therapy/therapies.

- Patient's treating clinician has made the decision to provide clinical care or
treatment prior to patient consent and independently of the purpose of ALZ-NET.

Exclusion Criteria;

• < 18 years of age.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/04/2024. Questions regarding updates should be directed to the study team contact.